Clinical Trial Update: HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating reduced intensity conditioning and hematopoietic stem cell transplantation for high-risk hemoglobinopathies, including sic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major
• Sickle Cell Disease

Snippet

Sponsor: Northwell Health | Conditions: Sickle Cell Disease, Beta Thalassemia-Major | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-11-05